A new paradigm for disease prevention

RNA medicines are at a critical moment in time. mRNA vaccines dominate the headlines in the wake of the COVID-19 pandemic. But huge advances are also being made in RNAi and antisense technologies. Our understanding of RNA chemistry continues to mature. Delivery tools are increasingly sophisticated and impactful. Advances in genomics and gene editing are driving new approaches. And exciting work targeting RNA with small molecules is emerging.

With that in mind, we can’t wait to bring the community together, face-to-face, for the second annual RNA Leaders Europe Congress.

So, if you’re passionate about all things RNA do join us, and more than 600 biotech, pharmaceutical, investment, regulatory and scientific professionals at the RNA Leaders Europe Congress. You’ll hear the latest advances in RNA chemistry, get clinical updates from the companies developing new therapies and source the services partners who are helping to deliver drugs to patients.

Meet the 2022 speakers

500+ companies actively developing RNA therapeutics

4000+ live clinical trials for RNA therapeutics and vaccines

2 major mRNA vaccine approvals in 2020

3 RNAi therapeutic approvals in the past 4 years

1500+ investors actively looking to fund RNA technology

96 successful fund raises by mid 2021 (vs 101 total in 2020)

More than $1.65bn raised by RNA biotech mid 2021

Millions of lives saved by mRNA vaccines to date

Become a partner

Do you offer products or services to support RNA drug development? The pharma and biotech executives attending RNA Leaders World Congress want to meet you! They are looking for:

• • Delivery platforms
  • Contract research
  • Equipment supply

• • Target discovery tools
  • CDMO and CMC
  • Reagent providers

• • RNA editing tools
  • RNA analysis
  • Legal services

Subscribe to hear speaker announcements, ticket offers and more